COSMO Pharmaceuticals N.V.(DE:C43)
€62.40-0.40 (-0.64%)
DE:C43
COSMO Pharmaceuticals N.V. financials statements
€62.40
At close:-0.40 (-0.64%)
COSMO Pharmaceuticals N.V. (C43) Ratios
4 Followers
COSMO Pharmaceuticals N.V. Ratios
DE:C43's free cash flow for Q2 2026 was €-9.56M. For the 2026 fiscal year, DE:C43's free cash flow was decreased by €-2.18M and operating cash flow was €-7.38M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.18 | 4.19 | 3.98 | 1.57 | 12.99 |
| Quick Ratio | 6.77 | 3.91 | 3.42 | 1.51 | 12.37 |
| Cash Ratio | 2.19 | 0.92 | 1.96 | 0.95 | 9.35 |
| Solvency Ratio | 0.07 | 1.03 | 0.07 | 0.10 | 0.10 |
| Operating Cash Flow Ratio | -0.46 | 3.36 | 0.88 | 0.17 | 0.59 |
| Short-Term Operating Cash Flow Coverage | -82.39 | 1168.42 | 165.75 | 0.19 | 94.82 |
| Net Current Asset Value | € 59.77M | € 60.58M | € -22.72M | € 10.29M | € -17.04M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.23 | 0.21 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.00 | 0.38 | 0.34 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.28 | 0.25 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 |
| Financial Leverage Ratio | 1.27 | 1.30 | 1.31 | 1.66 | 1.59 |
| Debt Service Coverage Ratio | -0.98 | 574.50 | 1.55 | 0.22 | 1.70 |
| Interest Coverage Ratio | -57.54 | 1302.41 | 0.72 | 3.01 | 1.23 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.17 | 0.16 |
| Interest Debt Per Share | 0.28 | 0.14 | 0.64 | 11.14 | 10.62 |
| Net Debt to EBITDA | -22.68 | -0.25 | -2.46 | -0.26 | -1.61 |
| Profitability Margins | |||||
| Gross Profit Margin | 46.53% | 92.55% | 57.60% | 81.62% | 76.73% |
| EBIT Margin | -10.00% | 57.51% | 6.62% | 32.94% | 17.06% |
| EBITDA Margin | 2.17% | 62.11% | 21.23% | 45.79% | 27.37% |
| Operating Profit Margin | -10.00% | 55.81% | 6.62% | 27.48% | 17.06% |
| Pretax Profit Margin | -0.88% | 57.49% | 1.65% | 23.97% | 36.89% |
| Net Profit Margin | -3.46% | 49.94% | -5.32% | 16.87% | 33.30% |
| Continuous Operations Profit Margin | -3.35% | 49.92% | -5.10% | 17.15% | 33.31% |
| Net Income Per EBT | 393.03% | 86.87% | -321.93% | 70.38% | 90.29% |
| EBT Per EBIT | 8.81% | 103.01% | 24.93% | 87.23% | 216.22% |
| Return on Assets (ROA) | -0.59% | 20.60% | -0.89% | 2.27% | 2.69% |
| Return on Equity (ROE) | -0.75% | 26.74% | -1.17% | 3.77% | 4.29% |
| Return on Capital Employed (ROCE) | -1.79% | 24.88% | 1.16% | 4.97% | 1.42% |
| Return on Invested Capital (ROIC) | -1.78% | 21.57% | -3.59% | 2.72% | 1.28% |
| Return on Tangible Assets | -1.38% | 45.81% | -2.83% | 4.67% | 5.30% |
| Earnings Yield | -0.20% | 12.02% | -0.56% | 1.70% | 2.04% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.10 | 14.09 | 3.26 | 2.64 | 2.66 |
| Payables Turnover | 4.95 | 2.18 | 4.48 | 2.47 | 3.69 |
| Inventory Turnover | 5.38 | 1.47 | 2.77 | 1.63 | 1.15 |
| Fixed Asset Turnover | 3.41 | 9.17 | 3.25 | 3.37 | 2.14 |
| Asset Turnover | 0.17 | 0.41 | 0.17 | 0.13 | 0.08 |
| Working Capital Turnover Ratio | 0.67 | 2.31 | 0.99 | 0.56 | 0.27 |
| Cash Conversion Cycle | 83.26 | 106.94 | 162.18 | 214.12 | 354.53 |
| Days of Sales Outstanding | 89.12 | 25.91 | 111.94 | 138.05 | 137.15 |
| Days of Inventory Outstanding | 67.82 | 248.23 | 131.73 | 223.68 | 316.28 |
| Days of Payables Outstanding | 73.68 | 167.20 | 81.49 | 147.62 | 98.89 |
| Operating Cycle | 156.94 | 274.15 | 243.67 | 361.73 | 453.42 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | 9.93 | 1.41 | 2.02 | 0.75 |
| Free Cash Flow Per Share | -0.99 | 9.58 | 1.14 | 1.58 | 0.24 |
| Dividend Paid and CapEx Coverage Ratio | -0.31 | 4.30 | 1.07 | 1.45 | 1.48 |
| Capital Expenditure Coverage Ratio | -2.74 | 28.73 | 5.17 | 4.55 | 1.48 |
| Operating Cash Flow Coverage Ratio | -2.73 | 73.79 | 12.35 | 0.19 | 0.07 |
| Operating Cash Flow to Sales Ratio | -0.11 | 0.61 | 0.24 | 0.33 | 0.19 |
| Free Cash Flow Yield | -0.88% | 14.14% | 2.07% | 2.55% | 0.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -491.19 | 8.32 | -178.94 | 58.94 | 49.12 |
| Price-to-Sales (P/S) Ratio | 17.21 | 4.15 | 9.51 | 9.94 | 16.36 |
| Price-to-Book (P/B) Ratio | 3.74 | 2.22 | 2.09 | 2.22 | 2.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -113.83 | 7.07 | 48.19 | 39.17 | 259.19 |
| Price-to-Operating Cash Flow Ratio | -155.31 | 6.82 | 38.86 | 30.55 | 84.41 |
| Price-to-Earnings Growth (PEG) Ratio | 4.78 | -0.00 | 1.38 | -3.17 | -0.15 |
| Enterprise Value Multiple | 771.06 | 6.44 | 42.34 | 21.46 | 58.16 |
| Enterprise Value | 1.75B | 1.07B | 834.11M | 1.00B | 1.04B |
| EV to EBITDA | 771.06 | 6.44 | 42.34 | 21.46 | 58.16 |
| EV to Sales | 16.71 | 4.00 | 8.99 | 9.82 | 15.92 |
| EV to Free Cash Flow | -110.58 | 6.80 | 45.55 | 38.70 | 252.22 |
| EV to Operating Cash Flow | -150.87 | 6.57 | 36.73 | 30.19 | 82.14 |
| Tangible Book Value Per Share | 8.72 | 9.12 | 3.07 | 4.44 | 6.88 |
| Shareholders’ Equity Per Share | 30.18 | 30.46 | 26.21 | 27.82 | 30.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -2.80 | 0.13 | 4.09 | 0.28 | 0.10 |
| Revenue Per Share | 6.57 | 16.31 | 5.76 | 6.22 | 3.86 |
| Net Income Per Share | -0.23 | 8.14 | -0.31 | 1.05 | 1.29 |
| Tax Burden | 3.93 | 0.87 | -3.22 | 0.70 | 0.90 |
| Interest Burden | 0.09 | 1.00 | 0.25 | 0.73 | 2.16 |
| Research & Development to Revenue | 0.31 | 0.00 | 0.20 | 0.15 | 0.17 |
| SG&A to Revenue | 0.26 | 0.03 | 0.06 | 0.03 | 0.04 |
| Stock-Based Compensation to Revenue | 0.02 | 0.01 | 0.04 | 0.02 | 0.02 |
| Income Quality | 3.20 | 1.06 | 14.82 | 1.36 | 0.53 |
Currency in EUR
